Mirum Pharmaceuticals, Inc. (MIRM)

NASDAQ: MIRM · IEX Real-Time Price · USD
24.58
-1.25 (-4.84%)
At close: Apr 12, 2024, 4:00 PM
24.23
-0.35 (-1.42%)
After-hours: Apr 12, 2024, 4:36 PM EDT
-4.84%
Market Cap 1.15B
Revenue (ttm) 186.37M
Net Income (ttm) -163.42M
Shares Out 46.61M
EPS (ttm) -4.00
PE Ratio n/a
Forward PE 104.17
Dividend n/a
Ex-Dividend Date n/a
Volume 466,132
Open 25.70
Previous Close 25.83
Day's Range 24.23 - 25.97
52-Week Range 24.23 - 35.56
Beta 1.14
Analysts Strong Buy
Price Target 54.00 (+119.69%)
Earnings Date May 2, 2024

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 2019
Employees 264
Stock Exchange NASDAQ
Ticker Symbol MIRM
Full Company Profile

Financial Performance

In 2023, MIRM's revenue was $186.37 million, an increase of 141.85% compared to the previous year's $77.06 million. Losses were -$163.42 million, 20.5% more than in 2022.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price forecast is $54.0, which is an increase of 119.69% from the latest price.

Price Target
$54.0
(119.69% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

3 days ago - Business Wire

Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome.

11 days ago - Business Wire

US FDA approves expanded use of Mirum's liver disease drug

The U.S Food and Drug Administration has approved the expanded use of Mirum Pharmaceuticals' oral drug to treat itching caused by a liver disorder in patients aged five years and older, the company sa...

4 weeks ago - Reuters

Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pfic--Mirum's LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis.

4 weeks ago - Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel the...

5 weeks ago - Business Wire

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update.

6 weeks ago - Business Wire

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024.

7 weeks ago - Business Wire

Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #leadership--Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer.

3 months ago - Business Wire

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates.

3 months ago - Business Wire

Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference.

3 months ago - Business Wire

Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia.

4 months ago - Business Wire

Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference.

5 months ago - Business Wire

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Presents New Data at The Liver Meeting®.

5 months ago - Business Wire

Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference.

5 months ago - Business Wire

Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update.

5 months ago - Business Wire

Mirum Pharmaceuticals to Present New Data at The Liver Meeting®

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #algs--Mirum Pharmaceuticals to Present New Data at The Liver Meeting®.

5 months ago - Business Wire

Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023.

6 months ago - Business Wire

Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis.

6 months ago - Business Wire

Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN.

6 months ago - Business Wire

Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #cerebrotendinousxanthomatosis--Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xant...

6 months ago - Business Wire

Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting.

7 months ago - Business Wire

Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference.

7 months ago - Business Wire

Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer.

7 months ago - Business Wire

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Thera...

Other symbols: TVTX
7 months ago - Business Wire

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update.

9 months ago - Business Wire